Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (441-450 of 721) with videos related to

Pageof 73
Sort By:
Journal of Clinical Medicine|October 2, 2020
<sup>18</sup>F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?Yan Li, Laura Isabel Mueller, Jan Peter Neuhaus, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Life (Basel, Switzerland)|April 30, 2021
Theranostics in Boron Neutron Capture TherapyWolfgang A G Sauerwein, Lucie Sancey, Evamarie Hey-Hawkins, et al.
EJNMMI Research|May 16, 2015
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapyConstantin Lapa, Rudolf A Werner, Christina Bluemel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 1, 2010
First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECTThomas Wendler, Ken Herrmann, Andreas Schnelzer, et al.
Theranostics|April 1, 2015
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imagingHans Jürgen Wester, Ulrich Keller, Margret Schottelius, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2023
Renal and Multiorgan Safety of <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry SubstudyKen Herrmann, Kambiz Rahbar, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 23, 2016
Synthesis and preclinical evaluation of an Al<sup>18</sup>F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligandStefano Boschi, Jason T Lee, Seval Beykan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 27, 2017
Establishing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerWolfgang P Fendler, Andreea D Stuparu, Susan Evans-Axelsson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 5, 2022
EANM practice guideline for quantitative SPECT-CTJohn C Dickson, Ian S Armstrong, Pablo Minguez Gabiña, et al.
Pageof 73

Showing results (441-450 of 721) with videos related to

Sort By:
Pageof 73
Journal of Clinical Medicine|October 2, 2020
<sup>18</sup>F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?Yan Li, Laura Isabel Mueller, Jan Peter Neuhaus, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Life (Basel, Switzerland)|April 30, 2021
Theranostics in Boron Neutron Capture TherapyWolfgang A G Sauerwein, Lucie Sancey, Evamarie Hey-Hawkins, et al.
EJNMMI Research|May 16, 2015
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapyConstantin Lapa, Rudolf A Werner, Christina Bluemel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 1, 2010
First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECTThomas Wendler, Ken Herrmann, Andreas Schnelzer, et al.
Theranostics|April 1, 2015
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imagingHans Jürgen Wester, Ulrich Keller, Margret Schottelius, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2023
Renal and Multiorgan Safety of <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry SubstudyKen Herrmann, Kambiz Rahbar, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 23, 2016
Synthesis and preclinical evaluation of an Al<sup>18</sup>F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligandStefano Boschi, Jason T Lee, Seval Beykan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 27, 2017
Establishing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerWolfgang P Fendler, Andreea D Stuparu, Susan Evans-Axelsson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 5, 2022
EANM practice guideline for quantitative SPECT-CTJohn C Dickson, Ian S Armstrong, Pablo Minguez Gabiña, et al.
Pageof 73